Cybin (CYBN.NE) announced today that it has completed its 51st pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (IND)-enabling studies. Read Full Article: https://equity.guru/2021/06/22/cybin-cybn-ne-completes-51st-pre-clinical-psychedelic-molecule-study/
Latest News
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
